Transgene Biotek
Transgene Biotek Share Price Chart
Transgene Biotek last traded at ₹2.66 (2026-10-13). Over the past month the stock moved -7.0%, three months the stock moved -15.0%, year the stock moved -30.7%. Its closing range over 52 weeks is ₹2.11 – ₹4.31, with the latest close 38.3% below the high.
Closing prices up to 2026-10-13.
About Transgene Biotek
Incorporated in 1990, Transgene Biotek Ltd is in the business of Research & Development[1]
Business Overview:[1] TBL started as a Biotechnology company engaged in the manufacturing and selling diagnostic kits. The company expanded to biotech research, including the research and development of vaccines, oncology, New drug delivery technologies etc. Currently, the company has a product and technology portfolio covering Oncology, Oral Drug Delivery and Bio-generics.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Transgene Biotek reported sales of ₹0.06 crore (+20.0%) and net profit of ₹-0.39 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 0.06 | -0.06 | -100.00 | -0.39 | -0.05 |
| Mar 2026 | 0.05 | -0.28 | -560.00 | -0.46 | -0.06 |
| Dec 2025 | 0.05 | -0.05 | -100.00 | -0.37 | -0.05 |
| Sep 2025 | 0.05 | -0.08 | -160.00 | -0.39 | -0.05 |
| Jun 2025 | 0.05 | -0.13 | -260.00 | -0.43 | -0.06 |
| Mar 2025 | 0.08 | -0.54 | -675.00 | -0.71 | -0.09 |
| Dec 2024 | 0.08 | -0.09 | -112.50 | -0.09 | -0.01 |
| Sep 2024 | 0.06 | -0.07 | -116.67 | -0.07 | -0.01 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +20.0% | +60.0% | +60.0% | +0.0% | -16.7% | -37.5% | -37.5% | +20.0% |
| Operating profit growth | – | – | – | – | – | – | – | – |
| Net profit growth | – | – | – | -315.0% | – | – | – | – |
| EPS growth | – | – | – | -300.0% | – | – | – | – |
| OPM % | -116.7% | -112.5% | -675.0% | -260.0% | -160.0% | -100.0% | -560.0% | -100.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Transgene Biotek reported sales of ₹0.21 crore (-19.2%) and net profit of ₹-1.65 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 0.21 | -0.54 | -257.14 | -1.65 | -0.22 |
| Mar 2025 | 0.26 | -1.12 | -430.77 | -0.68 | -0.09 |
| Mar 2024 | 0.23 | -0.60 | -260.87 | -0.66 | -0.09 |
| Mar 2023 | 0.06 | -0.62 | -1,033.33 | -6.01 | -0.79 |
| Mar 2022 | 0.09 | -0.46 | -511.11 | -10.40 | -1.37 |
| Mar 2021 | 0.17 | -0.53 | -311.76 | -10.43 | -1.38 |
| Mar 2020 | 0.00 | -0.87 | – | -10.96 | -1.45 |
| Mar 2019 | 0.07 | -0.68 | -971.43 | -8.79 | -1.16 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -41.7% | -100.0% | – | -47.1% | -33.3% | +283.3% | +13.0% | -19.2% |
| Operating profit growth | – | – | – | – | – | – | – | – |
| Net profit growth | – | – | – | – | – | – | – | – |
| EPS growth | – | – | – | – | – | – | – | – |
| OPM % | -971.4% | – | -311.8% | -511.1% | -1033.3% | -260.9% | -430.8% | -257.1% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Transgene Biotek.
Get Free AI Stock Analysis FREE →Latest News
-
Transgene Biotek closes trading window from July 1 until Q1FY27 results - scanx.trade
Frequently Asked Questions
What is the share price of Transgene Biotek today?
Transgene Biotek shares were last quoted at ₹2.66 (+7.7% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Transgene Biotek?
Transgene Biotek has a price-to-earnings (P/E) ratio of -13.48 and a price-to-book (P/B) ratio of 2.70. The industry P/E is 53.45.
What is the 52-week high and low of Transgene Biotek?
The 52-week high of Transgene Biotek is ₹4.39 and the 52-week low is ₹1.83.
What is the market cap of Transgene Biotek?
The market capitalisation of Transgene Biotek is about ₹21.44 crore.
How did Transgene Biotek perform in its latest quarterly results?
In the latest quarter (Jun 2026), Transgene Biotek reported sales of ₹0.06 crore (+20.0%) and net profit of ₹-0.39 crore, compared with the same quarter last year.
Is Transgene Biotek a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Transgene Biotek has a 3-year ROE of -10.00%, 3-year profit growth of 20.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Transgene Biotek?
Promoters hold about 21.68% of Transgene Biotek.
Which sector does Transgene Biotek belong to?
Transgene Biotek belongs to the Hospital & Healthcare Services sector.
Other Hospital & Healthcare Services stocks
- Apollo Hospitals Enterprises
- Max Healthcare Institute
- Manipal Health Enterprises
- Aster DM Quality Care
- Fortis Healthcare
- Global Health
- Narayana Hrudayalaya
- Krishna Institute of Medical Sciences
All Hospital & Healthcare Services stocks · Browse all stocks A–Z